Precigen Sees Unusually High Options Volume (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock traders purchased 11,169 call options on the company. This is an increase of approximately 1,645% compared to the average daily volume of 640 call options.

Precigen Stock Performance

Shares of PGEN stock traded up $0.05 on Friday, hitting $1.39. 1,939,095 shares of the stock traded hands, compared to its average volume of 2,291,726. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The firm's 50-day moving average price is $0.93 and its two-hundred day moving average price is $1.06. The stock has a market capitalization of $407.09 million, a PE ratio of -2.53 and a beta of 1.65.

Institutional Trading of Precigen

Several hedge funds have recently made changes to their positions in PGEN. SG Americas Securities LLC lifted its holdings in Precigen by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 12,578 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Precigen by 10.2% in the third quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company's stock valued at $159,000 after purchasing an additional 15,525 shares during the period. Stifel Financial Corp raised its position in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company's stock valued at $90,000 after purchasing an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company's stock worth $79,000 after purchasing an additional 18,097 shares during the period. Hedge funds and other institutional investors own 33.51% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PGEN shares. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and issued a $6.00 price objective (up previously from $4.00) on shares of Precigen in a report on Thursday. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.